Analysts' Actions: A BBT DECK DUK JCP


Agilent ( A) was downgraded at Stifel Nicolaus to hold from buy. Valuation call, said Stifel Nicolaus.

Aflac ( AFL) was upgraded at FBR Capital Markets to outperform from market perform. $71 price target. Company is seeing higher sales and managing its solvency margin ratio better, FBR Capital Markets said.

BB&T ( BBT) was upgraded at Oppenheimer to outperform from perform. Valuation call, based on a $40 price target, Oppenheimer said.

Beacon Roofing ( BECN) was downgraded at Robert Baird to neutral from outperform. $39 price target. Estimates also cut, given lower near-term demand, Robert Baird said.

Cepheid ( CPHD) was downgraded at Bank of America/Merrill Lynch to neutral. Valuation call, based on a $41 price target, BofA/Merrill said.

Cree ( CREE) was upgraded at Canaccord Genuity to buy from hold. $80 price target. Company is leveraged to continued demand for lighting and is seeing lower costs, Canaccord Genuity said.

Carter's ( CRI) was upgraded at Goldman Sachs to buy. $89 price target. Company deserves a premium valuation, Goldman said.

Deckers Outdoor ( DECK) was upgraded at Canaccord Genuity to buy from hold. $80 price target. Positive checks show improving fundamentals across the industry, Canaccord Genuity said.

Duke Energy ( DUK) was upgraded at Deutsche Bank to buy from hold. $74 price target. Sector appears attractively valued, Deutsche Bank said.

FirstEnergy ( FE) was upgraded at Jefferies to hold from underperform. $36.50 price target. Valuation call, Jefferies said.

Finish Line ( FINL) was downgraded at Goldman Sachs to sell from neutral. Valuation call, based on a $22 price target, Goldman Sachs said.

Hess ( HES) was downgraded at Societe Generale to hold from buy. $86 price target. Restructuring process could take longer than expected, Societe Generale said.

H&R Block ( HRB) was upgraded at Morgan Stanley to overweight. $33 price target. GoHealth relationship can drive near-term growth, Morgan Stanley said.

J.C. Penney ( JCP) was downgraded at Argus to hold from buy. Share offering could dilute investors by more than 40%, Argus said.

LKQ ( LKQ) was upgraded at Robert Baird to outperform from neutral. $38 price target. Europe can drive near-term growth, Robert Baird said.

If you liked this article you might like

What a Difference a Day Makes for New SEC Rule

Jim Cramer: Agilent Technology Has Been One of My Favorites

Jim Cramer -- Agilent Is 'Continuing to Defy Gravity'

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis